Literature DB >> 16621364

High throughput microsomal stability assay for insoluble compounds.

Li Di1, Edward H Kerns, Susan Q Li, Susan L Petusky.   

Abstract

High throughput metabolic stability assays are widely implemented in drug discovery to guide structural modification, predict in vivo performance, develop structure-metabolic stability relationships, and triage compounds for in vivo animal studies. However, these methods are often developed and validated using commercial drugs. Many drug discovery compounds differ from commercial drugs, with many having high lipophilicity, high molecular weight and low solubility. The impact of very low solubility on metabolic stability assay results was explored. Two metabolic stability assays, the 'aqueous dilution method' and the 'cosolvent method, were compared. For commercial drugs and most discovery compounds having reasonable drug-like properties, the two methods gave comparable results. For highly lipophilic, insoluble drug discovery compounds, the 'aqueous dilution method' gave artificially higher stability results. The cosolvent method performs compound dilutions in solutions with higher organic solvent content and adds solutions directly to microsomes to assist with solubilization, minimize precipitation and reduce non-specific binding to plastics. This method is more applicable in drug discovery where compounds of a wide range of solubility are studied.

Mesh:

Substances:

Year:  2006        PMID: 16621364     DOI: 10.1016/j.ijpharm.2006.03.007

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  22 in total

1.  Optimization of propafenone analogues as antimalarial leads.

Authors:  David J Lowes; W Armand Guiguemde; Michele C Connelly; Fangyi Zhu; Martina S Sigal; Julie A Clark; Andrew S Lemoff; Joseph L Derisi; Emily B Wilson; R Kiplin Guy
Journal:  J Med Chem       Date:  2011-10-10       Impact factor: 7.446

2.  In vitro and in vivo activities of HPi1, a selective antimicrobial against Helicobacter pylori.

Authors:  Ekaterina Gavrish; Binu Shrestha; Chao Chen; Ida Lister; E Jeffrey North; Lei Yang; Richard E Lee; Angel Han; Bronwyn Williams; David Charnuska; Ken Coleman; Kim Lewis; Michael D LaFleur
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

3.  Development of QSAR models for microsomal stability: identification of good and bad structural features for rat, human and mouse microsomal stability.

Authors:  Yongbo Hu; Ray Unwalla; R Aldrin Denny; Jack Bikker; Li Di; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2009-11-24       Impact factor: 3.686

4.  Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.

Authors:  Yan-Yan Zhang; Yong Liu; Shahila Mehboob; Jin-Hua Song; Teuta Boci; Michael E Johnson; Arun K Ghosh; Hyunyoung Jeong
Journal:  Xenobiotica       Date:  2013-10-30       Impact factor: 1.908

5.  Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.

Authors:  Qinghui Wang; Kinsie E Arnst; Yi Xue; Zi-Ning Lei; Dejian Ma; Zhe-Sheng Chen; Duane D Miller; Wei Li
Journal:  Eur J Med Chem       Date:  2018-02-19       Impact factor: 6.514

6.  Amide conjugates of ketoprofen and indole as inhibitors of Gli1-mediated transcription in the Hedgehog pathway.

Authors:  Neeraj Mahindroo; Michele C Connelly; Chandanamali Punchihewa; Lei Yang; Bing Yan; Naoaki Fujii
Journal:  Bioorg Med Chem       Date:  2010-05-07       Impact factor: 3.641

7.  Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties.

Authors:  E Jeffrey North; Michael S Scherman; David F Bruhn; Jerrod S Scarborough; Marcus M Maddox; Victoria Jones; Anna Grzegorzewicz; Lei Yang; Tamara Hess; Christophe Morisseau; Mary Jackson; Michael R McNeil; Richard E Lee
Journal:  Bioorg Med Chem       Date:  2013-02-26       Impact factor: 3.641

8.  Small Molecule Inhibition of the Ubiquitin-specific Protease USP2 Accelerates cyclin D1 Degradation and Leads to Cell Cycle Arrest in Colorectal Cancer and Mantle Cell Lymphoma Models.

Authors:  Mindy I Davis; Rajan Pragani; Jennifer T Fox; Min Shen; Kalindi Parmar; Emily F Gaudiano; Li Liu; Cordelle Tanega; Lauren McGee; Matthew D Hall; Crystal McKnight; Paul Shinn; Henrike Nelson; Debasish Chattopadhyay; Alan D D'Andrea; Douglas S Auld; Larry J DeLucas; Zhuyin Li; Matthew B Boxer; Anton Simeonov
Journal:  J Biol Chem       Date:  2016-09-28       Impact factor: 5.157

9.  A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study.

Authors:  Yang Wang; Jing Ma; Elisabeth D Martinez; Dong Liang; Huan Xie
Journal:  J Pharm Biomed Anal       Date:  2020-08-25       Impact factor: 3.935

10.  Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.

Authors:  Mindy I Davis; Stefan Gross; Min Shen; Kimberly S Straley; Rajan Pragani; Wendy A Lea; Janeta Popovici-Muller; Byron DeLaBarre; Erin Artin; Natasha Thorne; Douglas S Auld; Zhuyin Li; Lenny Dang; Matthew B Boxer; Anton Simeonov
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.